2024
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients
Brahmer J, Long G, Hamid O, Garon E, Herbst R, Andre T, Armand P, Bajorin D, Bellmunt J, Burtness B, Choueiri T, Cohen E, Diaz L, Shitara K, Kulkarni G, McDermott D, Shah M, Tabernero J, Vogel A, Zinzani P, Jafari N, Bird S, Snyder E, Gause C, Bracco O, Pietanza M, Gruber T, Ribas A. Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients. European Journal Of Cancer 2024, 199: 113530. PMID: 38295556, PMCID: PMC11227881, DOI: 10.1016/j.ejca.2024.113530.Peer-Reviewed Original ResearchConceptsImmune-mediated adverse eventsAdverse eventsInfusion reactionsSafety profileClinical trialsPembrolizumab discontinuationPembrolizumab monotherapyNon-small cell lung cancerSafety of pembrolizumabDose of pembrolizumabTreated with prednisoneCell lung cancerLow steroid dosesPopulation of patientsSteroid doseMedian durationPembrolizumabAE onsetPooled analysisLung cancerCancer clinical trialsSafety dataPatientsCancer typesInfusion
2023
Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review
Lozar T, Wang W, Gavrielatou N, Christensen L, Lambert P, Harari P, Rimm D, Burtness B, Kuhar C, Carchman E. Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review. Viruses 2023, 15: 2320. PMID: 38140561, PMCID: PMC10748233, DOI: 10.3390/v15122320.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaTriple-negative breast cancerCancer typesPredictive significancePrognostic factorsClinical outcomesPrognostic significanceCell carcinomaHuman cancersCervical squamous cell carcinomaNeck squamous cell carcinomaAvailable clinical evidenceCochrane Central RegisterInferior clinical outcomesPositive prognostic factorNegative predictive factorNegative prognostic factorWeb of ScienceCentral RegisterControlled TrialsCervical cancerClinical evidencePredictive factorsPancreatic cancerEligible studies
2009
Targeting EGFR resistance networks in head and neck cancer
Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS. Targeting EGFR resistance networks in head and neck cancer. Cellular Signalling 2009, 21: 1255-1268. PMID: 19258037, PMCID: PMC2770888, DOI: 10.1016/j.cellsig.2009.02.021.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaResponse of patientsPersonalized treatment approachesTumor progenitor cellsTypes of cancerAntibody agentsClinical outcomesCell carcinomaNeck cancerTreatment modalitiesInflammatory agentsTherapeutic strategiesTreatment approachesViral infectionEGFR/ErbB1Individual tumorsCancer typesProgenitor cellsCancerEGFREpigenetic modulationSurvival responseBiological featuresDevelopmental lineageOncoprotein
2003
Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era
Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. Journal Of Nuclear Cardiology 2003, 10: 132-139. PMID: 12673177, DOI: 10.1067/mnc.2003.7.Peer-Reviewed Original ResearchConceptsCongestive heart failureDoxorubicin therapyBaseline LVEFHeart failureCumulative doxorubicin doseLower baseline LVEFNormal baseline LVEFCancer-related deathCancer chemotherapeutic agentsLVEF monitoringLower LVEFDoxorubicin doseCardiac functionDoxorubicin chemotherapySerious toxicityLower incidenceEquilibrium radionuclideLVEFHigh incidenceERNA studiesAdditional casesChemotherapeutic agentsCancer typesPatientsTherapy